BI10773

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

Diabetes Mellitus, Type 2

Phase 1

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus

CompletedNCT01316341

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2011-03-31Updated: 2014-06-17

Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes

CompletedNCT01581658

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2012-04-01End: 2012-11-01Updated: 2017-08-14

Phase 3

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

CompletedNCT01177813

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2010-07-31Updated: 2014-06-16

Related Papers

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.

2016-06-17130 citations

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

Cardiovascular Diabetology2015-12-01131 citations

Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.

2015-06-1917 citations

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.

2014-09-0521 citations

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

2013-09-09349 citations